Increased expression of cathepsin L: A novel independent prognostic marker of worse outcome in hepatocellular carcinoma patients

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Ruan, Jian ^a   Zheng, Hang ^a   Fu, Wenguang ^b   Zhao, Peng ^c   Su, Ning ^d   Luo, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

^d GUANGZHOU CHEST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN L; MESSENGER RNA; TUMOR MARKER;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CARCINOGENICITY; COLONY FORMATION; CONTROLLED STUDY; CTSL GENE; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE;

ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CATHEPSIN L; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84911451371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112136     Document Type: Article

References (22)

1. Tung-Ping PR, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24.
2. Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, et al. (2007) Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 102: 1661- 1670, 1660, 1671.
3. Kirschke H, Langner J, Wiederanders B, Ansorge S, Bohley P (1977) Cathepsin L. A new proteinase from rat-liver lysosomes. Eur J Biochem 74: 293-301.
4. Reiser J, Adair B, Reinheckel T (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120: 3421-3431.
5. Kane SE, Gottesman MM (1990) The role of cathepsin L in malignant transformation. Semin Cancer Biol 1: 127-136.
6. Kenig S, Frangez R, Pucer A, Lah T (2011) Inhibition of cathepsin L lowers the apoptotic threshold of glioblastoma cells by up-regulating p53 and transcription of caspases 3 and 7. Apoptosis 16: 671-682.
7. Zheng X, Chu F, Chou PM, Gallati C, Dier U, et al. (2009) Cathepsin L inhibition suppresses drug resistance in vitro and in vivo: a putative mechanism. Am J Physiol Cell Physiol 296: C65-C74.
8. Zajc I, Hreljac I, Lah T (2006) Cathepsin L affects apoptosis of glioblastoma cells: a potential implication in the design of cancer therapeutics. Anticancer Res 26: 3357-3364.
9. Jean D, Rousselet N, Frade R (2006) Expression of cathepsin L in human tumor cells is under the control of distinct regulatory mechanisms. Oncogene 25: 1474-1484.
10. Strojnik T, Kavalar R, Trinkaus M, Lah TT (2005) Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect Prev 29: 448-455.
11. Colella R, Casey SF (2003) Decreased activity of cathepsins L+B and decreased invasive ability of PC3 prostate cancer cells. Biotech Histochem 78: 101-108.
12. Levicar N, Dewey RA, Daley E, Bates TE, Davies D, et al. (2003) Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther 10: 141-151.
13. Jagodic M, Vrhovec I, Borstnar S, Cufer T (2005) Prognostic and predictive value of cathepsins D and L in operable breast cancer patients. Neoplasma 52: 1-9.
14. Sullivan S, Tosetto M, Kevans D, Coss A, Wang L, et al. (2009) Localization of nuclear cathepsin L and its association with disease progression and poor outcome in colorectal cancer. Int J Cancer 125: 54-61.
15. Xu X, Yuan G, Liu W, Zhang Y, Chen W (2009) Expression of cathepsin L in nasopharyngeal carcinoma and its clinical significance. Exp Oncol 31: 102-105.
16. Macabeo-Ong M, Shiboski CH, Silverman S, Ginzinger DG, Dekker N, et al. (2003) Quantitative analysis of cathepsin L mRNA and protein expression during oral cancer progression. Oral Oncol 39: 638-647.
17. Miyamoto K, Iwadate M, Yanagisawa Y, Ito E, Imai J, et al. (2011) Cathepsin L is highly expressed in gastrointestinal stromal tumors. Int J Oncol 39: 1109-1115.
18. Yan JA, Xiao H, Ji HX, Shen WH, Zhou ZS, et al. (2010) Cathepsin L is associated with proliferation and clinical outcome of urothelial carcinoma of the bladder. J Int Med Res 38: 1913-1922.
19. Niedergethmann M, Wostbrock B, Sturm JW, Willeke F, Post S, et al. (2004) Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 29: 204-211.
20. Chauhan SS, Goldstein LJ, Gottesman MM (1991) Expression of cathepsin L in human tumors. Cancer Res 51: 1478-1481.
21. Yang Z, Cox JL (2007) Cathepsin L increases invasion and migration of B16 melanoma. Cancer Cell Int 7: 8.
22. Wille A, Gerber A, Heimburg A, Reisenauer A, Peters C, et al. (2004) Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells. Biol Chem 385: 665-670.